ArticleScientific reports2026
Immunometabolic determinants of hepatitis B vaccine seroprotection among Ethiopian adults.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) remains a critical public health issue in Ethiopia, where despite vaccination efforts, significant rates of non-seroprotection exist among vaccinated adults. Dyslipidemia and chronic inflammation are emerging as important immunometabolic factors influencing vaccine-induced immunity. This study aimed to investigate the impact of lipid profiles and inflammatory markers on hepatitis B vaccine seroprotection among healthcare providers who had completed hepatitis B vaccination in the northwestern region of Ethiopia. An institution-based cross-sectional study was conducted From May 22, 2024, to January 15, 2025 involving 422 healthcare providers. Socio-demographic and clinical data were collected and venous blood samples (7–9 milliliters) were obtained from each participant. Then, immunity following complete hepatitis B vaccination (anti-HBs) was measured using enzyme-linked immunosorbent assay (ELISA). Lipid profiles (HDL-C, LDL-C, TC, and TG) were analyzed using automated clinical chemistry analyzers. C-reactive protein (CRP) levels were quantified by latex agglutination turbidimetric immunoassay. The Systemic Immune-Inflammatory Index (SII) was calculated from complete blood count (CBC) results. Prevalence ratios (PRs) were calculated with 95% confidence intervals. The overall seroprotection rate was 73.7%. The seroprotection rate among participants aged 36–55 years was 47.9%. Additionally, high seroprotection rates were observed among participants with normal body mass index (83.3%), a healthy diet (80.7%), and normal HDL levels (83.0%), although these differences were not statistically significant. On the other hand, high LDL cholesterol level (APR = 0.67; 95% CI: 0.46 to 0.97; p = 0.032) and elevated SII (APR = 0.61; 95% CI: 0.40 to 0.93; p = 0.021) were significantly associated with increased risk of seroprotection reduction. This study underscores the importance of identifying composite immunometabolic and immunoinflammatory indices to predict and potentially mitigate poor vaccine outcomes, especially in populations facing ongoing infectious and metabolic challenges.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.